-
article
Sharma R, Pelland AA, Lajkosz K, Masih-Khan E, Vohra HS, Bhella S, Chen CI, Kukreti V, Stewart AK, Trudel S, Yang C, Reece DE, Venner C, Lancman G
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple Myeloma
Blood Cancer Discov
7 (3), 2026.
-
article
Pelland AA, Dumas M, Lemieux-Blanchard É and LeBlanc R, Côté J, Boudreault JS, Duquette D, Kaedbey R, Lalancette M, Larose F, Nikonova A, Pavic M, Shamy A, Roy J, Sebag M, Trudel S, Claveau JS
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
Curr Oncol
32 (4), 2025.
-
article
Pelland AA, Deschênes-Simard X, Savard X, Giguère P, Spillane D, Barabé F, Laroche V, Munger M, Gallagher G, Marcoux N, Cantin G, Chénard-Poirier M, Delage R, Lalancette M, Veilleux O, Assouline SE, Lemieux C
Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study
Leuk Lymphoma
65 (13), 2024.
